Kyverna Therapeutics Announces Landmark Results for Miv-cel in Stiff Person Syndrome: Statistically Significant, Durable Clinical Benefit Observed

Summary

• Kyverna Therapeutics (Nasdaq: KYTX) reports positive primary analysis results from the pivotal KYSA-8 trial of miv-cel (mivocabtagene autoleucel, KYV-101) in Stiff Person Syndrome (SPS).
• Single-dose miv-cel: Achieved robust, statistically significant, and durable clinical improvements across all endpoints in a severely impacted patient population.
• All patients discontinued chronic immunotherapies—an unprecedented outcome in SPS.
• Data presented at the American Academy of Neurology (AAN) Annual Meeting.
• BLA submission planned for this initial indication, with further potential in myasthenia gravis and other neurological autoimmune diseases.

Key Results and Potential Market Impact

Kyverna Therapeutics has unveiled compelling data that could fundamentally shift the treatment paradigm for SPS and impact the company’s valuation. The KYSA-8 Phase 2 trial, conducted in a patient group with inadequate response to off-label immunomodulatory treatments, demonstrated that a single dose of miv-cel led to rapid, statistically significant, and clinically meaningful improvements in mobility, disability, stiffness, and hypersensitivity.

• Primary endpoint met: Median improvement of 46% in the Timed 25-Foot Walk (T25FW) at Week 16 (p=0.0003).
• 81% of patients achieved ≥20% reduction from baseline in T25FW, with nearly one-third walking at the speed of healthy adults by Week 16.
• 67% of patients who required a walking aid at baseline no longer needed assistance at Week 16.
• All 26 patients discontinued chronic immunotherapies at Week 16 and remained off them through last follow-up.
• All secondary endpoints met with high statistical significance (p<0.0001):
  • Modified Rankin Scale (mRS): Mean improvement of -0.8 points
  • Hauser Ambulation Index (HAI): -1.6 points
  • Distribution-of-stiffness Index (DSI): -1.5 points
  • Heightened Sensitivity Scale (HSS): -3.2 points
• Exploratory endpoints: Showed deep, transient B-cell depletion, significant reductions in GAD65-autoantibody titers, and clinically meaningful improvements in physical/mental function (e.g., >4-fold improvement in 6-Minute Walk Test, normalization in SF-36 domains).

Safety Profile

• No high-grade cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS) observed.
• Manageable safety events: Grade 3/4 neutropenia in 4 patients; three serious treatment-related adverse events, all resolved fully without sequalae.
• Profile supports potential outpatient administration.

Market and Unmet Need Insights

SPS is a rare, serious, progressive neurologic autoimmune disease marked by muscle stiffness, spasms, and high rates of permanent disability and mortality. No FDA-approved treatments currently exist. Market estimates suggest around 6,000 diagnosed SPS patients in the U.S. Current standard-of-care (off-label immunotherapies, symptomatic medications, supportive care) is largely ineffective, as reinforced by a natural history study (n=153) showing minimal improvement in walking speed and increased reliance on walking aids over time.

These results, and the lack of any approved therapies, position miv-cel as a potential first- and only-in-class product, with the ability to reset the immune system and induce durable, drug-free remission after a single dose. This could drive significant uptake in a population with profound unmet need, and the data support expansion into other B-cell mediated autoimmune diseases, including myasthenia gravis (with updated data from KYSA-6 also presented at AAN).

Next Steps and Shareholder Considerations

• BLA submission for miv-cel in SPS is being prepared. If approved, this could be a major value inflection point for the company.
• Broader pipeline implications: Durable, robust results in SPS support confidence in miv-cel’s potential utility in other autoimmune indications (e.g., myasthenia gravis, multiple sclerosis, rheumatoid arthritis).
• Safety and outpatient potential: Outpatient administration would greatly expand market access and adoption.
• First-mover advantage: If approved, miv-cel could capture the SPS market, with no current direct competition.
• Upcoming catalysts: Investor conference call scheduled for April 22 at 7:00am ET to discuss these results and further myasthenia gravis data.

Company Overview

Kyverna Therapeutics is a late-stage clinical biopharmaceutical company focused on cell therapies for autoimmune diseases. Its lead candidate, miv-cel, is a fully human, autologous CD19-targeting CAR T-cell therapy with a CD28 co-stimulatory domain, designed for potency and tolerability. Kyverna is advancing miv-cel in SPS and generalized myasthenia gravis, with additional clinical and investigator-sponsored studies in multiple sclerosis and rheumatoid arthritis.

Conclusion

The KYSA-8 trial results represent a transformative advance for SPS patients and a significant potential value driver for Kyverna Therapeutics. With the potential to become the first approved therapy for SPS, durable single-dose efficacy, and a favorable safety profile, miv-cel could rapidly become the standard of care for this debilitating disease. Shareholders should closely monitor the BLA submission process, regulatory feedback, and upcoming data in other autoimmune indications, as these are likely to be major share price catalysts.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own research and consult with professional advisors before making any investment decisions. Forward-looking statements are subject to risks and uncertainties as detailed in Kyverna Therapeutics’ filings with the U.S. Securities and Exchange Commission.

View Kyverna Therapeutics, Inc. Historical chart here